Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 26 03 2020
accepted: 01 06 2020
pubmed: 24 8 2020
medline: 26 5 2021
entrez: 24 8 2020
Statut: ppublish

Résumé

We aimed to investigate the association between the different antiphospholipid antibodies (aPL) and both systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) manifestations. Patients from the RELESSER registry, a Spanish retrospective, cross-sectional, forty-five hospital registry of adult SLE patients, were included. Out of a total of 3,658 SLE patients, 1372 were aPL positive (555 of them fulfilled criteria for APS). All aPL types showed a negative association with cutaneous SLE manifestations. Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) were both associated with haematological, ophthalmological and neuropsychiatric manifestations. IgG isotypes were associated with a higher risk of lupus manifestations compared with IgM. We found that the risk of neuropsychiatric and ophthalmological manifestations significantly increased with a higher number of positive aPL whereas the risk of cutaneous symptoms showed a negative correlation. All types of aPL, and more strongly LA, were associated with non-criteria antiphospholipid syndrome (APS) manifestations such as thrombocytopenia and haemolytic anaemia. Moreover, LA and aCL (particularly IgG isotype) were also associated with Libman-Sacks endocarditis and cognitive impairment. This association was stronger with more than one positive aPL. All types of aPL were also associated with classic APS manifestations, although LA, IgG isotypes, and patients with more than one aPL displayed a higher risk. There is a hierarchy for aPL and the risk of APS and SLE manifestations. aCL, and especially LA, confer a higher risk for major organ involvement in SLE. IgG isotypes seem to have a more important role. The load of aPL confer a higher risk for APS and certain SLE manifestations.

Identifiants

pubmed: 32828148
pii: 15547
doi:

Substances chimiques

Antibodies, Antiphospholipid 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

555-563

Auteurs

Leyre Riancho-Zarrabeitia (L)

Rheumatology Department, Hospital Sierrallana, IDIVAL, Torrelavega, Spain.

Víctor M Martínez-Taboada (VM)

Rheumatology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Universidad de Cantabria, Spain. vmartinezt64@gmail.com.

Iñigo Rúa-Figueroa (I)

Rheumatology Department, Hospital Universitario Doctor Negrín, Las Palmas, Spain.

Fernando Alonso (F)

Unidad de Investigación, Sociedad Española de Reumatología, Madrid, Spain.

María Galindo-Izquierdo (M)

Rheumatology Department, Hospital Universitario Doce de Octubre, Madrid, Spain.

Juan Ovalles (J)

Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Alejandro Olivé-Marqués (A)

Rheumatology Department, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain.

Natalia Mena Vázquez (N)

Rheumatology Department, Hospital Regional Universitario de Málaga, Spain.

Jaime Calvo-Alén (J)

Rheumatology Department, Hospital Universitario Araba, Álava, Spain.

Raúl Menor Almagro (R)

Rheumatology Department, Hospital de Jerez, Cádiz, Spain.

Eva Tomero Muriel (E)

Rheumatology Department, Hospital Universitario La Princesa, Madrid, Spain.

Esther Uriarte Isacelaya (E)

Rheumatology Department, Hospital Universitario Donosti, San Sebastián, Spain.

Alina Boteanu (A)

Rheumatology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Mariano Andres (M)

Rheumatology Department, Hospital General Universitario de Alicante, Spain.

Mercedes Freire González (M)

Rheumatology Department, Hospital Universitario Juan Canalejo, A Coruña, Spain.

Gregorio Santos Soler (G)

Rheumatology Department, Hospital Marina Baixa, Alicante, Spain.

Maria Esther Ruiz-Lucea (ME)

Rheumatology Department, Hospital Universitario Basurto, Bilbao, Spain.

Mónica Ibáñez-Barceló (M)

Rheumatology Department, Hospital Universitario Son Llàtzer, Palma, Spain.

Iván Castellví (I)

Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Carlos Galisteo (C)

Rheumatology Department, Hospital Universitario Parc Taulí, Barcelona, Spain.

Víctor Quevedo Vila (V)

Rheumatology Department, Hospital Comarcal Monforte, Lugo, Spain.

Enrique Raya (E)

Rheumatology Department, Hospital Universitario Clínico San Cecilia, Granada, Spain.

Javier Narváez (J)

Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain.

Lorena Expósito (L)

Rheumatology Department, Hospital Universitario Canaries, Tenerife, Spain.

José A Hernández Beriaín (JA)

Rheumatology Department, Hospital Insular Universitario de Gran Canaria, Las Palmas, Spain.

Loreto Horcada (L)

Rheumatology Department, Complejo Hospitalario Universitario de Navarra, Spain.

Elena Aurrecoechea (E)

Rheumatology Department, Hospital Sierrallana, IDIVAL, Torrelavega, Spain.

José M Pego Reigosa (JM)

Complejo Hospitalario Universitario de Vigo IRIDIS Group, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH